Skip to content

ENLV - Enlivex Ltd. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchE

Enlivex Therapeutics Ltd

ENLV · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

E

ENLVEnlivex Therapeutics Ltd

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 21

52-wk high: $19.80
52-wk low: $1.46
Prev close: $11.37
Mkt cap: $30.2M
P/E: 0.0x
Beta: 1.47

Smart money

5 funds hold a position.

Real smart money

Funds holding this stock

5 holders

Combined position$1.7M

CW
Cathie Wood
Q2 2026 13F
$1.3M
position
TS
Two Sigma
Q2 2026 13F

Earnings

Reported Mar 25, 2026

Earnings came in 64.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

Fairly priced and running thin margins.

Net margin: 0.0%
P/E: 0.00
Market cap: $30M

Valuation

P/B0.01

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: ENLV
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $30.25M
Beta: 1.47

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

0.0x

Profit margin

+0.0%

Op margin

+0.0%

ROE

+126.2%

$101K

position

JS

Jim Simons

Q2 2026 13F

$74K

position

2 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 2 holders

Coverage gaps for ENLV

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.05+64.0%

-$0.14 expected

Next report

Reports Sep 4, 2026, in 14 days

126.2%

ROA-0.8%

Growth

Beta1.47